A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial
Phase 1 – testing safety in a small group of people
Conditions:
Locally advanced
recurrent
or metastatic breast
gastric
endometrial
and selected other solid tumors with positive expression for HER-2 (3+)
Sponsor: Vall D Hebron Institute Of Oncology
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 15 participants
БГ